Standard BioTools Inc. completed the divestiture of its SomaLogic business in 2026, refinancing its strategic focus around mass cytometry and microfluidics technologies. Despite a 10.6% revenue increase in 2025 to $277 million, the firm sustained sizable operating losses though improved from prior years. The company faces supply chain vulnerabilities due to reliance on single and sole source suppliers, compounded by a competitive market landscape and ongoing legal disputes tied to its recent merger activities. Liquidity remains strong, but persistent negative cash flow and loss generation highlight operational risk as the firm navigates its portfolio transition.